Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1149
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1149.)
© 1999 American Heart Association, Inc.
Goals of the New Editors
Donald D. Heistad, Editor, Arteriosclerosis, Thrombosis, Vascular Biology
As the Editorial Offices of
Arteriosclerosis, Thrombosis, and Vascular Biology move from
Los Angeles and San Diego to Iowa
City, we look back on changes in the
Journal and look forward
to challenges and goals. Alan Fogelman, with
Sam Rapaport, Jack
Hawiger, Göran Bondjers, Giulio Gabbiani, and
James Scott,
have been extraordinary Editors. This view was supported
by
the overwhelming majority of subscribers in a recent survey.
The
Journal has the highest impact factor of the journals that
focus on
atherosclerosis and lipids, and the number of
manuscripts
submitted has almost tripled during Dr Fogelman's
editorship.
The Journal has growing recognition in studies of
interaction
of blood with the vessel wall, and it is emerging as a
major
journal for studies of vascular biology. As a scientific
community,
we owe Drs Fogelman, Rapaport, Hawiger, Bondjers, Gabbiani,
Scott,
the Associate Editors, and the Editorial Board a hearty
thank-you.
What are our aims and goals for ATVB? We plan to publish basic and
clinical research related to:
vascular biology, including normal mechanisms and alteration during
disease. Vascular biology, which is a rapidly expanding area of
research, will be a major focus of the journal.
pathophysiology and complications of
atherosclerosis.
thrombotic mechanisms in blood vessels, particularly in relation to
interaction of blood and the vessel wall.
Authors and readers of ATVB have broad interests. Some appropriate
areas of research include studies of normal vascular biology, risk
factors for atherosclerosis, dyslipidemias,
thrombotic and antithrombotic mechanisms in blood and blood vessels,
and vascular abnormalities associated . . . [Full Text of this Article]